EINDHOVEN, Netherlands, Aug. 27, 2024 (GLOBE NEWSWIRE) — ONWARD Medical NV (Euronext: ONWD), the medical device company developing innovative spinal cord stimulation therapies to restore movement, function and independence in people with spinal cord injury (SCI), today announced that it will host a webcast to discuss its business highlights for the first half of 2024.
The webcast will take place on September 10, 2024 at 2:00 p.m. CET (8:00 a.m. ET) and will be hosted by CEO Dave Marver, who will discuss highlights of the first half of 2024 and provide a business update.
To participate in the webcast via Zoom, please register using this link.
Participation is also possible by telephone:
+32 2 290 9360 (Belgium)
+33 1 7095 0350 (France)
+49 69 3807 9884 (Germany)
+31 20 794 0854 (Netherlands)
+41 22 591 0156 (Switzerland)
+44 203 481 5240 (United Kingdom)
+1 346 248 7799 (US)
Additional phone numbers available
Meeting ID: 834 0031 2222
A replay of the webcast will be available on the Company’s website following the live event.
To learn more about ONWARD Medical’s commitment to partnering with the SCI community to develop innovative solutions to restore movement, function and independence after spinal cord injury, please visit ONWD.com.
*All CONTINUE® Medical devices and therapies, including but not limited to ARC-IM®ARC-EX®ARC-BCI™and ARC therapy™alone or in combination with a brain-computer interface (BCI), are experimental and not available for commercial use.
About ONWARD Medical
FURTHER® Medical is a medical device company developing therapies to restore movement, function and independence in people with spinal cord injury (SCI) and mobility impairments. Building on more than a decade of scientific discoveries and preclinical and clinical research at leading hospitals, rehabilitation clinics and neuroscience laboratories, the company has developed ARC Therapy™, which has been awarded ten Breakthrough Device Designations by the U.S. Food and Drug Administration (FDA).
ONWARD ARC Therapy is a targeted, programmed spinal cord stimulation delivered through the company’s external ARC-EX system.® or implantable ARC-IM® Platforms. ARC therapy can also be delivered through the company’s ARC-BCI™ platform, which combines the ARC-IM system with brain-computer interface (BCI) technology to restore movement after spinal cord injury through thought-based control.
The use of non-invasive ARC-EX therapy significantly improved upper extremity function after spinal cord injury in the global, pivotal Up-LIFT trial. The results were published by Natural medicine in May 2024. The Company has submitted its New Drug Application to the FDA for approval of the ARC-EX system in the US and is preparing its regulatory submission in Europe. In parallel, the Company is conducting clinical trials with its ARC-IM therapy, which demonstrated positive preliminary clinical results in improved blood pressure regulation following spinal cord injury. Additional ongoing clinical trials focus on the use of ARC-IM therapy to improve mobility following spinal cord injury and gait problems in Parkinson’s disease, as well as the use of the ARC-BCI platform to restore mind-controlled movement of the upper and lower limbs following spinal cord injury.
ONWARD Medical has its headquarters in Eindhoven (Netherlands), a science and development center in Lausanne (Switzerland) and a US office in Boston (Massachusetts). The company is listed on Euronext in Brussels and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com. You can also connect with us on LinkedIn and YouTube.
For media inquiries:
Aditi Roy, Vice President of Communications
[email protected]
For investor inquiries:
Amori Fraser, Finance Director
[email protected]
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking and reflect the current expectations and projections of the Company or, as the case may be, its directors regarding future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial impact of the plans and events described herein. A variety of factors, including, but not limited to, changes in demand, competition and technology, could cause actual events, performance or results to differ materially from those anticipated. Forward-looking statements in this press release regarding past trends or activities should not be read as a representation that such trends or activities will continue in the future. Therefore, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the forward-looking statements in this press release as a result of changed expectations or changes in events, conditions, assumptions or circumstances on which any such forward-looking statements are based. Neither the Company nor its advisors or agents nor any of its affiliates or the officers or employees of any of these persons warrant that the assumptions underlying such forward-looking statements are error-free nor do they assume responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecast developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD Medical devices and therapies mentioned herein, including but not limited to ARC-IM®ARC-EX®ARC-BCI™ and ARC Therapy™ are experimental and not available for commercial use.
